{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/05/27/3301719/0/en/Apogee-Therapeutics-Announces-Positive-16-Week-Part-B-Induction-Dose-Optimization-Results-from-Phase-2-APEX-Trial-of-Zumilokibart-in-Moderate-to-Severe-Atopic-Dermatitis.html", "message": "News view counter 757524 successfully enlarged"}